A safety trial of trifluridine/tipiracil for DPD-deficient patients
Treatments studied
Part of Cancer, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced colorectal or gastroesophageal cancer that has spread to other parts of your body.
- You have not received any previous treatment for your metastatic cancer.
- You have a known DPD deficiency, which means a blood test showed a high level of a substance called uracil.
- You are at least 18 years old and in generally good health (able to care for yourself).
- Your kidney and liver function are within acceptable limits based on recent blood tests.
- You agree to use effective birth control during the study and for 7 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
This study tests a real-world treatment with a combination drug called Trifluridine/Tipiracil for people with metastatic colorectal cancer. It aims to see how well it works and how safe it is in everyday medical practice.
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and who have already had surgery to remove as much cancer as possible. The goal is to see if this treatment can help control the cancer and improve outcomes.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.